Congresses

Title Yearsort descending
Discovering the mode of action of a novel chemical series active against mycobacteria and other microbial pathogens 2020
Repurposing beta-lactams for Buruli ulcer therapy 2020
Repurposing avermectins for the treatment of infections by non-tuberculous mycobacteria 2020
Repurposing beta-lactams for Buruli ulcer therapy, from the bench to the clinic. 2021
Strategies to elucidate the mode of action of the avermectins against mycobacteria 2021
Beta-lactams against Mycobacterium kansasii 2021
Novel in vitro synergistic combinations in the treatment of non-tuberculous mycobacteria 2021
Enzymatic inhibition of Mycobacterium tuberculosis DprE1 protein by the anti-parasitic selamectin lacks translation into phenotypic activity 2021
Approaches to elucidate the mode of action of a novel chemical series active against mycobacteria 2021
Clinical trial design optimisation and dose rationale for the treatment of Buruli ulcer antibiotic combination therapy 2021
OPTIKA, A New High Content Drug Combination Kill Kinetic Assay 2022
Implementing best practises on data generation and reporting of Mycobacterium tuberculosis time kill assays: a case study of standardized protocol within the ERA4TB consortium 2022
Shortening Buruli Ulcer treatment: the BLMS4BU clinical trial 2022
The veterinary anthelmintic selamectin inhibits the mycobacterial DprE1 enzyme 2022
Repurposing Beta-lactams for Buruli Ulcer Therapy, from the Bench to the Clinic 2022
Recapitulation of pulmonary SARS-CoV-2 infection in vitro in a novel 3D human lung organoid model with innate immune and stromal cells 2022
Shortening Buruli ulcer treatment: the BLMs4BU clinical trial 2022
Shortening Buruli Ulcer treatment: the BLMS4BU clinical trial 2022
Study of in vitro and in vivo activity of a novel compound against Mycobacterium abscessus for the treatment of cystic fibrosis infections 2022
A drug candidate against Mycobacterium abscessus and other cystic fibrosis pathogens 2022

Pages